Abstract: The incidence of chronic kidney disease (CKD) is high, about 10～15% of adults have CKD, and the incidence is even increasing. CKD is also an independent risk factor for cardiovascular events. On the other hand, cardiovascular disease (CVD) is the first cause of death in CKD patients. Clinical research has now confirmed that aspirin has important role in the primary and secondary prevention of CVD. However, clinical research has no conclusion about aspirin in the prevention of CVD in CKD patients. Here we review available literature and summarize that the effect of low-dose aspirin is unknown for the prevention of cardiovascular events in CKD patients without hemodialysis and on hemodialysis. Therefore, high quality and prospective clinical trials are required in the future.

Key words: aspirin, chronic kidney disease, cardiovascular event